CHICAGO — Eli Lilly's once-daily weight-loss pill Foundayo significantly reduced breathing interruptions during sleep in adults with obesity and moderate-to-severe obstructive sleep apnea, meeting the main goal of a late-stage trial, the company said on Monday, November 9. The results, from the Phase 3 ATTAIN-OSA programme, were presented the same day at the American Heart Association Scientific Sessions in Chicago and published simultaneously in the Journal of the American Medical Association (JAMA).
Source: Reuters
Foundayo is the brand name for orforglipron, a GLP-1 drug. It is already approved by the U.S. Food and Drug Administration (FDA) for obesity — Scientific American reported that approval came in April 2026 — but it is NOT yet approved for sleep apnea. Lilly said it plans to submit Foundayo to the FDA for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026.
What the trial actually measured
ATTAIN-OSA was really two separate randomized, double-blind, placebo-controlled studies running for 52 weeks. One enrolled 363 people who could not or would not use positive airway pressure (PAP) therapy — the mask-and-machine treatment whose most common form is CPAP. The other enrolled 349 people who had used PAP for at least three months and kept using it during the study. All participants had obesity or overweight alongside moderate-to-severe sleep apnea.
Severity is scored by the apnea-hypopnea index (AHI), which counts breathing pauses or shallow-breathing events per hour of sleep. In the group not using PAP, participants started at an average AHI of 50.7. Foundayo cut that by 21.1 events per hour — a 43.8% reduction — compared with a reduction of 5.5 events per hour on placebo, according to the figures reported from the trial. In plain terms, the average person in that group went from roughly 50 interruptions an hour to about 30.
In the group using PAP, participants started at an average AHI of 57.6, and Foundayo cut it by 18.3 events per hour — a 27.5% reduction — compared with 4.3 events per hour on placebo. In the non-PAP group, 47.2% of participants achieved an AHI reduction of 50% or more, and 31.5% reached remission or mild disease. In the PAP group, 33.7% achieved a reduction of 50% or more, and 19.6% reached remission or mild disease. Both studies met their primary endpoints.
Most participants still had sleep apnea at the end of the trial. In the PAP group, about four in five still had disease above the mild range, and an accompanying JAMA editorial noted that a substantial proportion of participants remained classified with moderate-to-severe sleep apnea at week 52. The trial also did not separate how much of the benefit came from weight loss itself: participants on Foundayo lost about 11% of their body weight in both groups.
Weight, oxygen and the side effects readers should know
Participants taking Foundayo lost about 28 pounds on average over the 52 weeks in both groups — reported as 28.0 lb (11.5%) without PAP and 28.2 lb (11.2%) with PAP. The drug also reduced sleep apnea-related hypoxic burden — a measure of how deeply and for how long blood-oxygen levels fall during sleep — by 55.9% in participants not using PAP therapy and by 45.8% in those using PAP therapy, Lilly said.
Side effects matter for any daily pill. Reporting summarizing the trial put gastrointestinal adverse events at 68% to 71% of participants taking orforglipron — the nausea, vomiting and gut symptoms familiar from the GLP-1 class. The 52-week window also leaves long-term durability, adherence and weight-regain patterns unmeasured. Anyone considering this class of medicine needs a doctor's assessment; the trial averages describe groups, not any one person's likely result.
Why sleep apnea matters — including for truckers
Obstructive sleep apnea is the condition in which the airway repeatedly collapses during sleep, causing pauses in airflow longer than 10 seconds. It can cause loud snoring, choking, sleep deprivation and headaches, and because it repeatedly drops blood-oxygen levels it can increase the risks of heart problems. As many as 936 million adults worldwide are estimated to experience the condition, although most are never formally diagnosed, according to the estimate cited by Scientific American.
Study co-author Vaishnavi Kundel, an associate professor of medicine at the Icahn School of Medicine at Mount Sinai, said in a company statement: 'We know there's a two-way relationship between sleep and cardiovascular health, and the repeated drops in oxygen that happen with obstructive sleep apnea can strain blood pressure and the heart over time. Foundayo significantly reduced breathing interruptions and drops in oxygen during sleep, while also improving blood pressure and inflammation.' Daniel Drucker, an endocrinologist at the Lunenfeld-Tanenbaum Research Institute in Ontario who was not involved in the trial but has previously consulted for Lilly, noted that every change to the GLP-1 backbone raises the question of overall and cardiovascular safety again, and said that if approved, orforglipron 'may represent a new option for individuals preferring once-daily administration of a GLP-1 medicine' for sleep apnea.
For Awaaz Punjab's readers the condition has a direct working-life angle: untreated sleep apnea causes daytime sleepiness, and commercial drivers in the United States are routinely screened for it because drowsy driving in a heavy truck is a safety risk for everyone on highways such as I-5, I-80 and I-95. A once-daily pill — if the FDA approves it for this use — would be a needle-free option alongside, not instead of, the mask machines many drivers already struggle to use consistently in a cab. That 'if' is the key word: until the FDA acts, Foundayo's approved use remains weight management, and no reader should treat it as an approved apnea treatment.
What happens next
Lilly said it will file for FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026. The FDA will then review the ATTAIN-OSA data — the AHI reductions, the oxygen and weight results, and the side-effect profile — before deciding whether the sleep-apnea indication is added. Foundayo was approved for weight loss earlier this year and, according to the trial reporting, generated $184 million in global sales in the third quarter, including $124 million in the United States. Awaaz Punjab will report the FDA filing and any decision as a follow-up; the earlier development this story builds on is Foundayo's original obesity approval, and this trial is the first late-stage evidence for the sleep-apnea use.